This is a preview of subscription content, log in via an institution to check access.
References
Dhainaut JFA, Vincent JL, Richard C, et al. CDP571, a humanized antibody to human tumor necrosis factor-alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. Crit Care Med 1995 Sep; 23: 1461–9
Rankin ECC, Choy EHS, Kassimos D, et al. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 1995 Apr; 34: 334–42
Warren BF, Watkins PE, Foulkes R, et al. Anti TNF alpha treatment of a model of human ulcerative colitis. Gut 1994; 35 Suppl. 2: 50
Bloxham DP. Therapeutic applications of anti-TNF monoclonal antibodies. Expert Opin Investig Drugs 1994 Sep; 3: 907–12
Watkins PE, Foulkes R, Stephens S, et al. The treatment of ulcerative colitis with anti-tumour necrosis factor alpha antibody. Falk Symposium Inflammatory Bowel Diseases; 1995 Jun 29; 178
Celltech’s Ab promising in colitis. Scrip 1995 Sep 26; 2063: 22
Stack WA, Mann SD, Roy AJ, et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn’s disease. Lancet 1997 Feb 22; 349: 521–4
Rights and permissions
About this article
Cite this article
CDP 571. Drugs R&D 1, 253–255 (1999). https://doi.org/10.2165/00126839-199901030-00014
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-199901030-00014